New drug combo targets rare cancers in tiny trial
NCT ID NCT05715281
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether combining two immunotherapy drugs, tiragolumab and atezolizumab, can shrink advanced rare solid tumors. Twelve patients whose cancers have not responded to standard treatment will receive the drugs and undergo biopsies and blood tests to measure immune activity. The main goal is to see if the drugs boost immune cell levels in tumors and are safe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- tiragolumab and atezolizumab (immunotherapy drugs)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with rare solid tumors that have not responded to standard therapy.
- What could go wrong
- This is a very small early-phase trial (12 participants) focused on immune response, not yet proven to shrink tumors or improve survival. Side effects from immunotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED RARE MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
Bethesda, Maryland, 20892, United States
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210, United States